Technology evaluation: EPI-2010, EpiGenesis.

Abstract	EpiGenesis, in collaboration with Taisho and Chiesi, is developing EPI-2010, a 21-mer phosphorothioate respirable antisense oligonucleotide (RASON) that blocks the synthesis of the adenosine A1 receptor, for the potential treatment of asthma.
Authors	Zhaoda Zhang
Journal	Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 4 Issue 3 Pg. 275-80 (Jun 2002) ISSN: 1464-8431 [Print] England
PMID	12139314 (Publication Type: Journal Article, Review)
Chemical References	Anti-Asthmatic Agents EPI2010 Oligodeoxyribonucleotides, Antisense Phosphates
Topics	Administration, Inhalation Anti-Asthmatic Agents (administration & dosage, chemistry, therapeutic use) Asthma (drug therapy, genetics, physiopathology) Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Disease Models, Animal Humans Oligodeoxyribonucleotides, Antisense (administration & dosage, metabolism, pharmacology, therapeutic use) Phosphates (administration & dosage, chemistry, therapeutic use) Respiration Disorders (drug therapy, prevention & control) Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!